Source · Select Committees · Public Accounts Committee

Recommendation 4

4

The introduction of rapid-results testing was supposed to be a ‘gamechanger’ but confusion persists over...

Recommendation
The introduction of rapid-results testing was supposed to be a ‘gamechanger’ but confusion persists over why and how it should be used in different community settings. Around one-third of people who have coronavirus are asymptomatic. There is now a widespread roll-out of rapid tests (primarily lateral flow device (LFD) tests, which give results in 30 minutes) for local authority use and in other community settings, such as schools and workplaces. To support this roll-out, the government allocated a further £7 billion to NHST&T in December 2020 on top of £3 billion already budgeted. The Department had already purchased 384 million LFD test kits. However, a number of reports have raised concerns about the effectiveness and risks of mass testing using LFD tests, given their lower accuracy compared to laboratory- processed tests, particularly the higher risk of ‘false negatives’ (people who actually have the virus getting a negative result). NHS T&T told the committee that a negative test result means that an individual is around 77% likely to be negative for Covid-19. Initial NHST&T and PHE guidance for schools suggested that they could use LFD tests for daily tests as an alternative to self-isolation, but this advice has now been withdrawn. On 21 January, PHE announced that it would pause or scale back the roll-out of mass testing in schools, with further evaluation needed because COVID-19: Test, track and trace (part 1) 7 of the emergence of the new, more transmissible variant of the virus. Following the Prime Minister’s announcement on 22 February, schools will test students and staff regularly using LFD tests, but guidance on rapid testing in schools is yet to be updated. Recommendation: The Department and NHST&T should set out clearly how and why mass rapid testing should be used in each of the settings where roll-out is planned, alongside clear targets and updates on progress in the various sectors. Any plans should take account of the approved purpose and accura
Government Response Acknowledged
HM Government Acknowledged
4.1 The government agrees with the Committee’s recommendation. Target implementation date: June 2021 4.2 Regular rapid tests are a vital tool in helping to identify cases of coronavirus that would otherwise not be found. Around one in three cases show no symptoms, and testing with rapid lateral flow devices 1 6 (LFDs) helps find these cases and prevent the spread of infection. Regular rapid testing was initially focused on asymptomatic NHS and care home staff to support the resilience of health and care services and protect vulnerable people. It was then extended on a targeted basis to settings such as schools, universities and workplaces, and from April 2021 targeted eligibility has been replaced with a universal testing offer available to all. This includes a new pharmacy collect option alongside expanded home delivery. 4.3 Alongside the department’s universal testing offer, it is in the process of reviewing its plan on asymptomatic testing and intend to publish this information, with updates on progress in each setting, and with agreed targets focused on impact and outcomes. 4.4 All plans take account of the performance of available tests. Extensive and ongoing clinical evaluation, and MHRA approval, support the use of lateral flow devices and PCR (polymerase chain reaction) tests for asymptomatic people. With some limited exceptions, we have not identified circumstances where LFD testing is not suitable, but its use complements existing regular PCR testing which has higher sensitivity but longer processing times. There are some circumstances where individuals may have physical difficulty in taking LFD and PCR tests and we are rapidly exploring alternative solutions for these groups. LFD testing forms part of a wider strategy to identify asymptomatic carriers, which includes contact tracing (including ‘backward’ contact tracing) and wastewater analysis.